IPAB Rejects Novartis Plea for New Tech Member (India)
This article was originally published in PharmAsia News
Executive Summary
The Intellectual Property Appellate Board (IPAB) in India has dismissed the application by Novartis to appoint a new technical member in place of former Patent Controller S Chandrasekhar to hear the pharma firm's appeal against the Patent Office's denial of patent to its blood cancer drug Glivec. Novartis officials said Chandrasekhar had a conflict of interest due to being the Patent Controller who denied the patent rights for Glivec. A Novartis spokesperson said, "Today's decision was a summary judgment and we will not know the panel's reasoning until a full written judgment is issued. We will consider our options once we see the full text." (Click here for more